Aarti Drugs launches dermatology product production at new Tarapur facility
Aarti Drugs Limited (NSE: AARTIDRUGS; BSE:524348), a Mumbai-based pharmaceutical powerhouse, has officially announced the start of its dermatology product production at its newly established facility in Tarapur, Maharashtra. As of January 30, 2024, the company has begun manufacturing an array of dermatology products, marking a significant step in its expansion strategy.
The new facility in Tarapur, situated adjacent to Aarti Drugs’ existing units, spans a vast 40,000 square feet area. Equipped with cutting-edge technology and adhering to the highest industry standards, this strategic development is in line with the company’s vision to solidify its position in the skincare market and contribute to healthcare advancements. The facility, a testament to the company’s commitment to innovation, will initially focus on catering to domestic demands with plans to explore export markets in the future.
Aarti Drugs’ foray into dermatology includes a comprehensive range of formulations tailored to address various skin conditions such as dermatitis, psoriasis, acne, and eczema. The company’s dedicated research and development efforts ensure that its product line evolves continuously to meet the changing needs of healthcare professionals and patients alike.
Aarti Drugs Steps into Dermatology Market with State-of-the-Art Tarapur Facility
The establishment of the Tarapur facility represents a significant investment of approximately Rs 150 to Rs 200 crores, partially financed through term loans and internal accruals. With an operational capacity of 24,000 MTPA, the facility is designed to meet the increasing demand for innovative skincare solutions.
Adhish Patil, CFO & COO of Aarti Drugs Limited, expressed his enthusiasm for the new venture, stating, “The commencement of dermatology product production at our Tarapur facility is an exciting milestone. This facility, with its state-of-the-art infrastructure and strict quality control measures, is set to be pivotal in our mission to enhance access to quality healthcare solutions. The dermatology segment is crucial for us, and with this expansion, we aim to meet the growing demand for innovative skincare treatments.”
Aarti Drugs Limited’s move into dermatology product manufacturing is a strategic decision reflecting the growing demand in the skincare market. This expansion not only boosts the company’s portfolio but also signifies its commitment to addressing diverse healthcare needs. The investment in the Tarapur facility demonstrates the company’s foresight in tapping into emerging markets and its dedication to providing quality healthcare solutions.